GeneDx Holdings Corp

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GeneDx reports robust growth, eyes profitability by 2025

GeneDx's strong financial performance in 2022 and growth projections for 2023 indicate a promising trajectory for the company.
Strategic shifts towards whole genome sequencing, fundraising success, and favorable market coverage position GeneDx well for future success.
While facing challenges in business transitions and financial management, GeneDx has opportunities to drive profitability through margin expansion and strategic partnerships.

GeneDx reports robust Q1 earnings, eyes profitability by 2025

GeneDx's Q1 2023 performance reflects strong revenue growth and strategic positioning for future profitability by 2025.
The company's focus on rare disease testing, pediatric settings, and genome testing, coupled with financial improvements, highlights its resilience.
Challenges include managing cash burn, navigating competition, and balancing cost reduction with growth investments.
Opportunities for GeneDx include expanding market share, strategic partnerships, innovation in testing, and comprehensive patient care.

GeneDx reports record revenue and market dominance in genomics

GeneDx's strong performance in Q2 2023 reflects robust revenue growth and market dominance in exome and genome testing. The company's strategic focus on cost optimization, revenue enhancement, and market expansion positions it well for future profitability and growth.

GeneDx reports robust Q3 results, targets profitability by 2025

GeneDx Holdings Corp shows strong performance in Q3 2023 with revenue of $53 million and improved gross margins, supported by a cost reduction plan and debt facility.
While facing challenges in claim denials and lengthy appeal processes, the company aims to drive revenue growth from exome and genome testing to achieve profitability by 2025.
Opportunities lie in capital allocation for growth initiatives and sustainable profitability through cost reduction efforts and strategic investments in R&D.

GeneDx reports strong Q4 results, targets profitability by 2025

GeneDx demonstrated robust financial performance in Q4 2023, with revenue growth, improved margins, and reduced cash burn, setting a positive trajectory for future profitability.
Strategic initiatives like realigned sales strategy and focus on exome and genome tests position GeneDx for sustained growth and increased profitability in the coming years.
While challenges exist in managing cash burn and achieving profitability targets, GeneDx's strong financial position, strategic partnerships, and market focus offer opportunities for continued success.

GeneDx's strong financial performance, strategic strengths, and growth opportunities position it well for future success and profitability.
While facing challenges such as high denial rates and the path to profitability, the company's proactive approach and market focus offer avenues for improvement.
By leveraging its competitive advantages, addressing challenges, and capitalizing on growth opportunities, GeneDx aims to sustain its growth trajectory and achieve profitability by 2025.

GeneDx reports robust Q2 earnings, eyes profitability amid market expansion

GeneDx Holdings Corp's Q2 2024 performance reflects strong revenue growth, margin expansion, and progress towards profitability.
The company's strengths lie in its focus on pediatric genetics, successful product mix transition, and strategic investments in genome sequencing.
Challenges include policy expansion hurdles, maintaining financial discipline, and achieving profitability amidst industry dynamics.
Opportunities for GeneDx include market expansion through partnerships, patient access programs, and operational efficiency enhancements.

GeneDx reports robust Q3 earnings, eyes growth in genetic testing

GeneDx Holdings Corp delivered a strong Q3 performance, achieving profitability and raising revenue guidance for the year.
The company's strategic strengths lie in its market leadership, advanced sequencing capabilities, and diversified revenue streams.
While facing challenges in balancing growth and innovation, GeneDx has opportunities to expand into new markets and drive long-term success.
By optimizing costs, focusing on efficiency, and investing strategically, GeneDx aims to maintain profitability and drive innovation in genetic testing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

C.H. Robinson Worldwide

Fulcrum Therapeutics Inc

Kinross Gold

Mercury General

KGC, MCY, WGS, CHRW and FULC have been added to the Zacks Rank #1 (Strong Buy) List on August 5, 2023.

New Strong Buy Stocks for August 5th

GeneDx Holdings Corp. (NASDAQ:WGS ) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Sabrina Dunbar - Commercial Chief of Staff Katherine Stueland - President and Chief Executive Officer Kevin Feeley - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies William Bonello - Craig Hallum Mark Massaro - BTIG Daniel Brennan - TD Cowen Matthew Sykes - Goldman Sachs Operator Good day and thank you for standing by. Welcome to the GeneDx Second Quarter 2024 Earnings Conference Call.

GeneDx Holdings Corp. (WGS) Q2 2024 Earnings Call Transcript

GeneDx Holdings Corp. (WGS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $1.65 per share a year ago.

GeneDx Holdings Corp. (WGS) Reports Q2 Loss, Tops Revenue Estimates

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the second quarter of 2024.

GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx announces enhancements to its Whole Genome Sequencing, aiming to accelerate diagnoses and shorten the diagnostic odyssey for patients.

GeneDx Announces Whole Genome Sequencing (WGS) Product Enhancements to Accelerate Diagnoses for More Patients

Apogee Enterprises

Tenet Healthcare

WGS, THC and APOG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 23, 2024.

Best Momentum Stocks to Buy for July 23rd

Kronos Worldwide

Seagate Technology Holdings PLC

Telefonica SA

KRO, TEF, STX, WGS and THC have been added to the Zacks Rank #1 (Strong Buy) List on July 23, 2024.

New Strong Buy Stocks for July 23rd

Does GeneDx Holdings Corp. (WGS) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes GeneDx Holdings Corp. (WGS) a Strong Momentum Stock: Buy Now?

American Axle & Manufacturing Hlds

BJ's Restaurants

Groupon

Enviri Corp

We have narrowed our search to five small-cap stocks. These stocks are: AXL, NVRI, GRPN, BJRI, WGS.

Small Caps Climb on Interest Rate Cut Expectations: 5 Picks

GENEDX HOLDINGS (WGS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About GENEDX HOLDINGS (WGS) Rating Upgrade to Strong Buy

Daktronics

Hess

Advanced Drainage Systems

Invest in companies like Daktronics (DAKT), Hess (HES), Advanced Drainage Systems (WMS), Apogee Enterprises (APOG) and GENEDX HOLDINGS (WGS) to make the most of higher efficiency levels.

5 Must-Buy Efficient Stocks to Enrich Your Portfolio

GeneDx (Nasdaq: WGS) today announced it will release financial results for the second quarter of 2024 after the market closes on Tuesday, July 30, 2024.

GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024

Acacia Research

CTO Realty Growth

DoubleDown Interactive Co Ltd

Immersion

Karat Packaging

NewLake Capital Partners, Inc.

Having a list of small-cap stocks with high growth potential is similar to uncovering hidden gems. These stocks offer significant upside potential for emerging sectors and innovative business models reshaping industries.

7 Small-Cap Stocks With Massive Potential Returns

-- New integration to streamline access for health systems and improve provider and patient journeys using Epic for electronic connections -- -- Increases commercial footprint and focus on accelerating utilization of rWGS services in neonatal intensive care units (NICUs) --

GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients

GeneDx Holdings Corp. focuses on delivering precise medical diagnostic outcomes through its genomic expertise and rare disease dataset. Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) are key revenue drivers, growing 96% in the first quarter. Increasing acceptance and coverage by major commercial payers and Medicaid for exome and genome testing.

GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing

STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access program, developed in partnership with leading biopharma companies, which aims to increase access to exome sequencing for pediatric epilepsy patients.

GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients

ProFrac Holding Corp

Exelixis

FTAI Aviation Ltd

MCBC Hlds

Oxford Lane Capital

With the earnings-reporting season having all but concluded, the windows for making insider purchases are generally open.

Insider Buying Heats Up at Fracker, Aircraft and Boat Makers, and More

STAMFORD, Conn., May 22, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in two upcoming investor conferences in June: Jefferies Healthcare Conference - New York City, New York Fireside chat on Wednesday, June 5 at 9:00 a.m.

GeneDx to Participate in Upcoming Investor Conferences

GeneDx Holdings Corp. (NASDAQ:WGS ) Q1 2024 Earnings Conference Call April 29, 2024 4:30 PM ET Company Participants Sabrina Dunbar - Commercial Chief of Staff Katherine Stueland - President and Chief Executive Officer Kevin Feeley - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen Mark Massaro - BTIG, LLC Matthew Sykes - Goldman Sachs Matthew Stanton - Jefferies Group LLC Operator Ladies and gentlemen, thank you for standing by, and welcome to the GeneDx First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

GeneDx Holdings Corp. (WGS) Q1 2024 Earnings Call Transcript

GeneDx Holdings Corp. (WGS) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $2.82 per share a year ago.

GeneDx Holdings Corp. (WGS) Reports Q1 Loss, Tops Revenue Estimates

Reported first quarter 2024 revenue from continuing operations 1 of $61.5M with 96% year-over-year growth of exome and genome test revenue Expanded first quarter 2024 adjusted gross margins 2 from continuing operations to 61% Narrowed first quarter 2024 adjusted net loss 2 to $8.5M and delivered 71% year-over-year cash burn reduction Raised guidance to deliver between $235M and $245M in FY 2024 revenue and reiterate path to profitability in 2025 GeneDx to host conference call today at 4:30 p.m. ET STAMFORD, Conn.

GeneDx Reports First Quarter 2024 Financial Results and Business Highlights

The Company will also participate in a World Orphan Drug Congress panel presentation highlighting the role of genomic sequencing in advancing precision medicine The Company will also participate in a World Orphan Drug Congress panel presentation highlighting the role of genomic sequencing in advancing precision medicine

GeneDx Announces Partnership with Komodo Health to Expand Access to World's Largest Rare Disease Dataset

Management will host a conference call on Monday, April 29, 2024 to discuss first quarter 2024 financial and operating results at 4:30 p.m. Eastern Time.

GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024

GENEDX HOLDINGS (WGS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why GENEDX HOLDINGS (WGS) Could be Great Choice for a Bottom Fisher

STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. Across one platform presentation, an industry symposium and six poster presentations, including one selected as a “Rapid Fire Poster Session,” an invitation-only presentation of the top 20 ACMG posters, GeneDx continues to demonstrate its industry leadership in shaping the future landscape of genomics.

GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics

News for GeneDx Holdings Corp Stock (WGS)